Status:
WITHDRAWN
Assessment of Mortality Rates in COVID-19 Infected Populations Treated With Repurposed Medications
Lead Sponsor:
Tabula Rasa HealthCare
Conditions:
COVID
Drug Effect
Eligibility:
All Genders
Brief Summary
This retrospective cohort study will include eligible patients that received a positive COVID-19 test and filled a new prescription for one of the repurposed medications (including hydroxychloroquine,...
Detailed Description
There is a deficit in literature assessing the risk associated with these repurposed medications in COVID-19 patients. The investigators propose to evaluate if the use of repurposed drugs including hy...
Eligibility Criteria
Inclusion
- Patients receiving services at a PrescribeWellness pharmacy;
- Patients who received a COVID-19 positive test at a PrescribeWellness Pharmacy or other certified COVID-19 test centers since February 1, 2020;
Exclusion
- Patients who received a COVID-19 negative test at a PrescribeWellness Pharmacy or other certified COVID-19 test centers since February 1, 2020;
- Patients who received COVID-19 repurposed drugs without laboratory-confirmed test for COVID-19 disease;
- Patients who were receiving COVID-19 repurposed drugs prior to February 1, 2020.
Key Trial Info
Start Date :
June 12 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 26 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04432350
Start Date
June 12 2020
End Date
May 26 2022
Last Update
September 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute
Orlando, Florida, United States, 32827